Tested Applications
| Positive WB detected in | A549 cells, HEK-293 cells, HepG2 cells, PC-3 cells, mouse testis tissue |
| Positive IHC detected in | human kidney tissue, mouse kidney tissue, human ovary tumor tissue, human placenta tissue, human liver tissue, human colon cancer tissue, rat adrenal gland tissue, human kidney tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF/ICC detected in | HepG2 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:1000-1:4000 |
| Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:200-1:800 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
12592-1-AP targets FDX1 in WB, IHC, IF/ICC, IP, CoIP, ELISA applications and shows reactivity with human, mouse, rat samples.
| Tested Reactivity | human, mouse, rat |
| Cited Reactivity | human, mouse, rat, sheep |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag3301 Product name: Recombinant human FDX1 protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 1-184 aa of BC017063 Sequence: MAAAGGARLLRAASAVLGGPAGRWLHHAGSRAGSSGLLRNRGPGGSAEASRSLSVSARARSSSEDKITVHFINRDGETLTTKGKVGDSLLDVVVENNLDIDGFGACEGTLACSTCHLIFEDHIYEKLDAITDEENDMLDLAYGLTDRSRLGCQICLTKSMDNMTVRVPETVADARQSIDVGKTS Predict reactive species |
| Full Name | ferredoxin 1 |
| Calculated Molecular Weight | 184 aa, 19 kDa |
| Observed Molecular Weight | 14 kDa |
| GenBank Accession Number | BC017063 |
| Gene Symbol | FDX1 |
| Gene ID (NCBI) | 2230 |
| RRID | AB_11182486 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | P10109 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
FDX1(Ferredoxin-1) is also named as ADX, FDX, YAH1, LOH11CR1D and belongs to the adrenodoxin/putidaredoxin family. It is a small iron-sulfur protein that transfers electrons from NADPH through ferredoxin reductase to a terminal cytochrome P450 and it can only reduce mitochondrial CYP enzymes that are essential in adrenal steroidogenesis, bile acid formation, and vitamin D synthesis. The full length has a transit peptide of 60 amino acids.
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for FDX1 antibody 12592-1-AP | Download protocol |
| IHC protocol for FDX1 antibody 12592-1-AP | Download protocol |
| WB protocol for FDX1 antibody 12592-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
FDX1 Polyclonal Antibody Summary
The FDX1 Polyclonal antibody (Catalog #12592-1-AP) has 266 total citations. It appears in high-impact journals including Nature, Cancer Cell, Molecular Cell, Signal Transduction & Targeted Therapy, Advanced Materials, Nature Communications, ACS Nano, Cell Discovery, Autophagy, Redox Biology, Advanced Science, Biomaterials, and Frontiers in Immunology, among many others. Research fields span cuproptosis, ferroptosis, cancer therapy and immunotherapy, copper/iron metabolism and mitochondria biology, cardiovascular and liver disease, neurobiology, osteoarthritis, and toxicology, with applications primarily in WB, IHC, and IF.
| Species | Application | Title |
|---|---|---|
Signal Transduct Target Ther Conductive coordination nanozyme prodrugs precisely trigger pyroptosis, cuproptosis and ferroptosis for in situ cancer vaccination | ||
Cancer Cell Radiotherapy promotes cuproptosis and synergizes with cuproptosis inducers to overcome tumor radioresistance
| ||
Imeta Clinical features and molecular landscape of cuproptosis signature-related molecular subtype in gastric cancer | ||
Adv Mater Multifunctional Copper-Phenolic Nanopills Achieve Comprehensive Polyamines Depletion to Provoke Enhanced Pyroptosis and Cuproptosis for Cancer Immunotherapy | ||
Adv Mater Oxygen Vacancy-Engineered CaCu(3)Ti(4)O(12) Nanocatalyst for Piezoelectrically Driven Cascade Apoptosis/Cuproptosis/Ferroptosis Therapy. |

































